A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

February 2, 2024

Study Completion Date

February 2, 2024

Conditions

Healthy Male

Interventions

DRUG

D-1553

D-1553 is a novel, targeted KRASG12C inhibitor.

Trial Locations (1)

Shanghai Xuhui District Central Hospital, Shanghai